{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:05:28Z","timestamp":1789290328567,"version":"build-2803163510"},"posted":{"date-parts":[[2026,9,10]]},"group-title":"Cancer Biology","reference-count":39,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"award":["R01CA272621"],"award-info":[{"award-number":["R01CA272621"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01CA272621"],"award-info":[{"award-number":["R01CA272621"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012639","name":"METAvivor","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100012639","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) tumors lack expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, limiting the availability of targeted therapeutic options. As a result, TNBC is characterized by a high propensity for metastasis, rapid recurrence, and poor overall prognosis. Despite significant research efforts, the molecular mechanisms that drive TNBC progression and metastasis remain incompletely understood.<\/jats:p>\n                  <jats:p>Y-box binding protein-1 (YB1) is a multifunctional DNA\/RNA-binding protein that regulates transcription, translation, and mRNA stability. Aberrant activation of YB1 has been implicated in multiple oncogenic processes, including proliferation, survival, invasion, metastasis, and therapy resistance in several cancer types, including TNBC. Our investigations have revealed a central role for YB1 in regulating key hallmarks of cancer that drive TNBC tumor progression and metastatic dissemination.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cell viability and drug sensitivity in TNBC cell lines were assessed using the MTT assay to determine IC\u2085\u2080 values for pharmacologic inhibitors. Western blotting and quantitative RT-PCR were used to quantify protein and mRNA expression levels in TNBC cell lines and tumor samples. Oncogenic phenotypes were evaluated using 2D colony formation assays, 3D tumorsphere growth assays, limiting dilution, and transwell migration assays to assess proliferative, stem-like, and migratory capacities. Cell cycle progression was analyzed using flow cytometry\u2013based assays. In vivo therapeutic efficacy was evaluated using preclinical xenograft and patient-derived xenograft (PDX) mouse models of TNBC to assess tumor growth and metastatic progression following treatment.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our studies demonstrate that the small-molecule inhibitor SU056, which specifically targets YB1 for degradation, significantly suppresses the oncogenic behavior of TNBC cell lines and tumors. Pharmacologic inhibition of YB1 reduced TNBC cell proliferation, clonogenic growth, tumorsphere formation, stemness and migratory capacity. Importantly, combined treatment with SU056 and the CDK4\/6 inhibitor palbociclib enhanced the inhibitory effect on TNBC cell growth and tumor progression compared with either agent alone. Mechanistically, both genetic and pharmacologic targeting of YB1 suppressed TNBC tumor growth and metastatic potential through modulation of the Cyclin D\/CDK4\/6\/Rb signaling axis, leading to inhibition of cell cycle progression and induction of G1 arrest.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>\n                    Collectively, these findings identify SU056\/CDK4\/6i combination as a potential therapeutic option for the treatment of Rb\n                    <jats:sup>+<\/jats:sup>\n                    -TNBC.\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.09.05.749600","type":"posted-content","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:00:16Z","timestamp":1789066816000},"source":"Crossref","is-referenced-by-count":0,"title":["The small molecule inhibitor SU056-mediated targeting of YB1 inhibits the Rb pathway in triple negative breast cancer tumors"],"prefix":"10.64898","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[{"name":"MetroHealth System, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeaji","family":"Kim","sequence":"additional","affiliation":[{"name":"MetroHealth System, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cleveland State University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen Weber","family":"Bonk","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-3088","authenticated-orcid":false,"given":"Ruth","family":"Keri","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Su","sequence":"additional","affiliation":[{"name":"Cleveland State University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-7633","authenticated-orcid":false,"given":"Khalid","family":"Sossey-Alaoui","sequence":"additional","affiliation":[{"name":"MetroHealth System, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"Case Comprehensive Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026091302001072000_2026.09.05.749600v1.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043"},{"key":"2026091302001072000_2026.09.05.749600v1.2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014"},{"key":"2026091302001072000_2026.09.05.749600v1.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098"},{"key":"2026091302001072000_2026.09.05.749600v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"2026091302001072000_2026.09.05.749600v1.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1208"},{"key":"2026091302001072000_2026.09.05.749600v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389"},{"key":"2026091302001072000_2026.09.05.749600v1.7","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2009.s.008"},{"key":"2026091302001072000_2026.09.05.749600v1.8","doi-asserted-by":"crossref","unstructured":"Pesch AM , Hirsh NH , Michmerhuizen AR , Jungles KM , Wilder-Romans K , Chandler BC , Liu M , Lerner LM , Nino CA , Ward C et al: RB expression confers sensitivity to CDK4\/6 inhibitor-mediated radiosensitization across breast cancer subtypes. JCI Insight 2022, 7(3).","DOI":"10.1172\/jci.insight.154402"},{"issue":"1","key":"2026091302001072000_2026.09.05.749600v1.9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41523-025-00845-5","article-title":"Knudsen ES: Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer","volume":"11","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"2026091302001072000_2026.09.05.749600v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110073"},{"key":"2026091302001072000_2026.09.05.749600v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv779"},{"key":"2026091302001072000_2026.09.05.749600v1.12","doi-asserted-by":"crossref","unstructured":"Tiwari A , Iida M , Kosnopfel C , Abbariki M , Menegakis A , Fehrenbacher B , Maier J , Schaller M , Brucker SY , Wheeler DL et al: Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers. Cancers (Basel ) 2020, 12(10).","DOI":"10.3390\/cancers12102795"},{"key":"2026091302001072000_2026.09.05.749600v1.13","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2202"},{"key":"2026091302001072000_2026.09.05.749600v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.03.017"},{"key":"2026091302001072000_2026.09.05.749600v1.15","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.19.5491"},{"key":"2026091302001072000_2026.09.05.749600v1.16","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.26.1.277-292.2006"},{"key":"2026091302001072000_2026.09.05.749600v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.99"},{"issue":"5","key":"2026091302001072000_2026.09.05.749600v1.18","doi-asserted-by":"crossref","first-page":"101552","DOI":"10.1016\/j.xcrm.2024.101552","article-title":"Inhibition of protein translational machinery in triple-negative breast cancer as a promising therapeutic strategy","volume":"5","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026091302001072000_2026.09.05.749600v1.19","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.11.4625-4637.2005"},{"key":"2026091302001072000_2026.09.05.749600v1.20","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22009"},{"key":"2026091302001072000_2026.09.05.749600v1.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1731-8"},{"key":"2026091302001072000_2026.09.05.749600v1.22","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2156"},{"key":"2026091302001072000_2026.09.05.749600v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2008.04.011"},{"key":"2026091302001072000_2026.09.05.749600v1.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0945"},{"key":"2026091302001072000_2026.09.05.749600v1.25","doi-asserted-by":"publisher","DOI":"10.2217\/14796694.5.2.153"},{"key":"2026091302001072000_2026.09.05.749600v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.365"},{"key":"2026091302001072000_2026.09.05.749600v1.27","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2363"},{"key":"2026091302001072000_2026.09.05.749600v1.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4056"},{"key":"2026091302001072000_2026.09.05.749600v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/nm0497-447"},{"key":"2026091302001072000_2026.09.05.749600v1.30","doi-asserted-by":"crossref","unstructured":"Rana PS , Wang W , Alkrekshi A , Markovic V , Khiyami A , Chan R , Perzynski A , Joseph N , Sossey-Alaoui K: YB1 Is a Major Contributor to Health Disparities in Triple Negative Breast Cancer. Cancers (Basel ) 2021, 13(24).","DOI":"10.3390\/cancers13246262"},{"issue":"8","key":"2026091302001072000_2026.09.05.749600v1.31","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.chembiol.2021.02.014","article-title":"Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer","volume":"28","year":"2021","journal-title":"Cell Chem Biol"},{"issue":"1","key":"2026091302001072000_2026.09.05.749600v1.32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1158\/2767-9764.CRC-22-0249","article-title":"Sossey-Alaoui K: The WAVE2\/miR-29\/Integrin-beta1 Oncogenic Signaling Axis Promotes Tumor Growth and Metastasis in Triple-negative Breast Cancer","volume":"3","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026091302001072000_2026.09.05.749600v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00272-0"},{"key":"2026091302001072000_2026.09.05.749600v1.34","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01634-3"},{"key":"2026091302001072000_2026.09.05.749600v1.35","doi-asserted-by":"crossref","unstructured":"Wang W , Rana PS , Alkrekshi A , Bialkowska K , Markovic V , Schiemann WP , Plow EF , Pluskota E , Sossey-Alaoui K: Targeted Deletion of Kindlin-2 in Mouse Mammary Glands Inhibits Tumor Growth, Invasion, and Metastasis Downstream of a TGF-beta\/EGF Oncogenic Signaling Pathway. Cancers (Basel ) 2022, 14(3).","DOI":"10.3390\/cancers14030639"},{"key":"2026091302001072000_2026.09.05.749600v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00272-0"},{"key":"2026091302001072000_2026.09.05.749600v1.37","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419"},{"key":"2026091302001072000_2026.09.05.749600v1.38","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0120-7"},{"key":"2026091302001072000_2026.09.05.749600v1.39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3157"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.05.749600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:00:21Z","timestamp":1789290021000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.09.05.749600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":39,"URL":"https:\/\/doi.org\/10.64898\/2026.09.05.749600","relation":{},"subject":[],"published":{"date-parts":[[2026,9,10]]},"subtype":"preprint"}}